Pharmacology

"Early identification of high-risk neonates may enable targeted strategies to support respiratory health," stated the study investigators.

Subgroup data show crinecerfont helps children with CAH reduce steroid use while maintaining or improving androstenedione levels across diverse patient groups.

Current prevention strategies include 2 injectables for infants and young children, namely palivizumab and nirsevimab.

Nirsevimab significantly reduces RSV-related hospitalizations, ICU admissions, and LRTIs in infants, but doesn’t shorten hospital stays, according to a recent study.

A look back at the FDA submissions and regulatory decisions in the pediatric health care space from April 2025.

In this article, we recap our top stories, expert interviews, and Q+A discussions from the 2025 Pediatric Academic Societies meeting.

In 3 studies evaluating the effects of probiotics on eczema, probiotics groups reported a greater reduction in symptoms than placebo groups, but only when the allergy was IgE mediated.

From the FDA approvals of dupilumab and maralixibat tablets to a new puzzler case study, get caught up with our weekly review article.

In the United States, maralixibat (Livmarli; Mirum Pharmaceuticals) is approved to treat both ALGS and PFIC, now in liquid and tablet formulations.

Editor-in-chief Tina Tan, MD, FAAP, FIDSA, FPIDS, highlights the April, 2025, issue of Contemporary Pediatrics, with a special focus on pediatric allergy awareness.

Flovent was discontinued in January 2024 due to the manufacturer electing to produce only an authorized generic version of the medication.

Aquestive Therapeutics reports positive pediatric study results for Anaphylm, supporting its FDA submission for treating severe allergic reactions.

A new clinical trial has found that omalizumab (Xolair; Genetech, Novartis) is more effective than oral immunotherapy (OIT) in treating multi-food allergy in individuals with severe allergic reactions to small amounts of common food allergens.

The approval marks a vital step toward care for urinary tract infections, helping to reduce recurrence and improve patients’ quality of life.

If approved, SYD-101 would be the first and only pharmaceutical option for the treatment of progression of pediatric myopia in the United States.

A presentation at the 46th National Association of Pediatric Nurse Practitioners (NAPNAP) conference explored the role of biologics in pediatric care, their applications in various conditions, and safety considerations for clinicians.

An overview of commercially available infant cardiorespiratory monitors and pulse oximeters in the home.

Metformin does not influence breastfeeding rates in patients with type 2 or early diabetes, according to recent data.

The FDA has accepted PTC Therapeutics' NDA for vatiquinone, a potential treatment for Friedreich's ataxia, with a decision expected by August 19, 2025.

A review of current guidelines in treatment and thromboprophylaxis.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

The designations follow the FDA acceptance of IND application for ABO-101 to treat PH1, with a phase 1/2 study planned in the first half of 2025.

A recap of the FDA submissions and regulatory decisions in pediatrics from January 2025.

"I’m all for reducing opioids, especially in neonates, for whom we are unsure of long-term adverse effects," stated Jon Matthew Farber, MD.

As a biosimilar to Actemra, tocilizumab-anoh in both IV and SC formulation is approved to treat rheumatoid arthritis, pJIA, sJIA, COVID-19, and giant cell arteritis.

The past year saw a number of approvals adding to the toolbox for atopic dermatitis, including new formulations that work in new mechanisms.

Editor-in-chief Tina Tan, MD, FAAP, FIDSA, FPIDS, highlights the January/February, 2025, issue of Contemporary Pediatrics.

The lead clinical trial investigator for a phase 3 study of crinecerfont in pediatric CAH patients breaks down the December 2024 FDA approval.

Neffy was first approved in September 2024 to treat type 1 allergic reactions in patients who weigh at least 66 lbs (33 kg).